Literature DB >> 10408303

Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy.

B Ozbakkaloglu1, O Tünger, S Sürücüoglu, M Lekili, A R Kandiloglu.   

Abstract

Although intravesical bacillus Calmette-Guerin (BCG) administration is an effective method in the treatment of superficial urinary bladder carcinoma, some complications may arise such as a granulomatous reaction either in the urinary tract or, in rare cases, outside the urinary tract. We report in this paper a case of granulomatous hepatitis following intravesical BCG administration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408303     DOI: 10.1023/a:1007119706336

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  10 in total

1.  The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ.

Authors:  S A Brosman
Journal:  J Urol       Date:  1985-07       Impact factor: 7.450

2.  Bacillus Calmette-Guerin immunotherapy for bladder cancer.

Authors:  D L Lamm
Journal:  J Urol       Date:  1985-07       Impact factor: 7.450

3.  Granulomatous hepatitis following intravesical bacillus Calmette-Guerin therapy for bladder carcinoma.

Authors:  H Y Marans; H M Bekirov
Journal:  J Urol       Date:  1987-01       Impact factor: 7.450

4.  Toxicity of intravesical BCG and its management in patients with superficial bladder tumors.

Authors:  E Orihuela; H W Herr; C M Pinsky; W F Whitmore
Journal:  Cancer       Date:  1987-08-01       Impact factor: 6.860

5.  Hypersensitivity systemic reaction following intravesical bacillus Calmette-Guerin: successful treatment with steroids.

Authors:  J M Molina; C Rabian; M F D'Agay; J Modai
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

6.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

7.  Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer.

Authors:  D L Lamm; V D Stogdill; B J Stogdill; R G Crispen
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

8.  Mycobacteremia and granulomatous hepatitis following initial intravesical bacillus Calmette-Guerin instillation for bladder carcinoma.

Authors:  D D Proctor; S Chopra; S C Rubenstein; J A Jokela; L Uhl
Journal:  Am J Gastroenterol       Date:  1993-07       Impact factor: 10.864

9.  A case of granulomatous hepatitis after intravesical bacillus Calmette-Guerin administration.

Authors:  D A Graziano; D Jacobs; R G Lozano; R L Buck
Journal:  J Urol       Date:  1991-10       Impact factor: 7.450

10.  Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer.

Authors:  A Morales
Journal:  J Urol       Date:  1984-09       Impact factor: 7.450

  10 in total
  3 in total

Review 1.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

2.  Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin.

Authors:  Aliye Soylu; Ali T Ince; Hakan Polat; Nurgul Yasar; Aydin Ciltas; Selvinaz Ozkara; Ali I Tasci
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-04-15       Impact factor: 3.944

3.  Acute Hepatitis Induced by Intravesical BCG Therapy: A Rare but Serious Complication.

Authors:  Hakima Abid; Mouna Figuigui; Sidi Adil Ibrahimi; Mohamed El Abkari; Mohamed Mzyiene; Soufiane Ennaciri; Ouima Justin Ziba; Mohamed Jamal El Fassi; Layla Tahiri Elousrouti; Laila Chbani
Journal:  Case Reports Hepatol       Date:  2021-06-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.